Works about IRINOTECAN

Results: 1795
    1

    Multi‐institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: A Kansai Clinical Oncology Group study (KCOG‐G1201)

    Published in:
    Journal of Obstetrics & Gynaecology Research, 2019, v. 45, n. 3, p. 671, doi. 10.1111/jog.13885
    By:
    • Mori, Taisuke;
    • Makino, Hiroshi;
    • Okubo, Tomoharu;
    • Fujiwara, Yoichiro;
    • Sawada, Morio;
    • Kuroboshi, Haruo;
    • Tsubamoto, Hiroshi;
    • Murakoshi, Homare;
    • Motohashi, Takashi;
    • Kitawaki, Jo;
    • Ito, Kimihiko
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.

    Published in:
    Journal of Neuro-Oncology, 2013, v. 113, n. 1, p. 127, doi. 10.1007/s11060-013-1098-2
    By:
    • Hargrave, Darren;
    • Geoerger, Birgit;
    • Frappaz, Didier;
    • Pietsch, Torsten;
    • Gesner, Lyle;
    • Cisar, Laura;
    • Breazna, Aurora;
    • Dorman, Andrew;
    • Cruz-Martinez, Ofelia;
    • Fuster, Jose;
    • Rialland, Xavier;
    • Icher, Céline;
    • Leblond, Pierre;
    • Ashley, David;
    • Perilongo, Giorgio;
    • Elliott, Martin;
    • English, Martin;
    • Clausen, Niels;
    • Grill, Jacques
    Publication type:
    Article
    15
    16
    17
    18
    19

    Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.

    Published in:
    Oncology, 2022, v. 100, n. 8, p. 449, doi. 10.1159/000525742
    By:
    • Yasuoka, Hidetoshi;
    • Naganuma, Atsushi;
    • Kurihara, Eishin;
    • Kobatake, Tsutomu;
    • Ijima, Masashi;
    • Tamura, Yuki;
    • Suzuki, Yuhei;
    • Hoshino, Takashi;
    • Ishida, Fumiya;
    • Hosaka, Hisashi;
    • Hatanaka, Takeshi;
    • Yoshida, Sachiko;
    • Aihara, Ryusuke;
    • Hosouchi, Yasuo;
    • Ishii, Norihiro;
    • Araki, Kenichiro;
    • Shirabe, Ken;
    • Uraoka, Toshio;
    • Kakizaki, Satoru
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.

    Published in:
    Oncology, 2017, v. 93, n. 5, p. 279, doi. 10.1159/000479154
    By:
    • Berenato, Rosa;
    • Morano, Federica;
    • Pietrantonio, Filippo;
    • Cotsoglou, Christian;
    • Caporale, Marta;
    • Infante, Gabriele;
    • Pellegrinelli, alessandro;
    • alessi, alessandra;
    • Battiston, Carlo;
    • Coppa, Jorgelina;
    • Padovano, Barbara;
    • Mennitto, alessia;
    • Niger, Monica;
    • Fucà, Giovanni;
    • Lazzati, Silvia;
    • Greco, Giorgio;
    • Delconte, Gabriele;
    • de Braud, Filippo;
    • Mazzaferro, Vincenzo;
    • Di Bartolomeo, Maria
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801).

    Published in:
    Oncology, 2014, v. 87, n. 1, p. 7, doi. 10.1159/000360989
    By:
    • Soeda, Hiroshi;
    • Shimodaira, Hideki;
    • Gamoh, Makio;
    • Ando, Hideaki;
    • Isobe, Hideki;
    • Suto, Takeshi;
    • Takahashi, Shin;
    • Kakudo, Yuichi;
    • Amagai, Kenji;
    • Mori, Takahiro;
    • Watanabe, Mika;
    • Yamaguchi, Takuhiro;
    • Kato, Shunsuke;
    • Ishioka, Chikashi
    Publication type:
    Article
    41
    42

    A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer.

    Published in:
    Oncology, 2013, v. 85, n. 6, p. 317, doi. 10.1159/000356018
    By:
    • Mizushima, Tsunekazu;
    • Ide, Yoshito;
    • Murata, Kohei;
    • Ohashi, Ichiro;
    • Yasumasa, Keigo;
    • Fukunaga, Mutsumi;
    • Takemoto, Hiroyoshi;
    • Tamagawa, Hiroshi;
    • Hasegawa, Junichi;
    • Hata, Taishi;
    • Takemasa, Ichiro;
    • Ikeda, Masataka;
    • Yamamoto, Hirofumi;
    • Sekimoto, Mitsugu;
    • Nezu, Riichiro;
    • Doki, Yuichiro;
    • Mori, Masaki
    Publication type:
    Article
    43
    44
    45
    46

    Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients.

    Published in:
    Oncology, 2012, v. 83, n. 2, p. 101, doi. 10.1159/000339541
    By:
    • Kato, Shunsuke;
    • Andoh, Hideaki;
    • Gamoh, Makio;
    • Yamaguchi, Takuhiro;
    • Murakawa, Yasuko;
    • Shimodaira, Hideki;
    • Takahashi, Shin;
    • Mori, Takahiro;
    • Ohori, Hisatsugu;
    • Maeda, Shun-ichi;
    • Suzuki, Takao;
    • Kato, Satoshi;
    • Akiyama, Shoko;
    • Sasaki, Yuka;
    • Yoshioka, Takashi;
    • Ishioka, Chikashi
    Publication type:
    Article
    47
    48
    49
    50